All In Biotech

Drug Trial Radar · NCT07870668

Intermittent Phentermine for Obesity and Body Composition

Adaptive Pharmacotherapy in Obesity: Intermittent Phentermine Improves Visceral Adiposity and Body Composition

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

600

Actual

Start

Mar 1, 2024

Primary completion

Jan 15, 2026

Study completion Jan 15, 2026

Sponsor

Lead sponsor
OSCAR MANUEL TORRES FALCONAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 21 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated the effects of intermittent phentermine treatment on body fat, estimated visceral adiposity, body composition, and tolerability in adults with overweight or obesity. A total of 600 adults aged 21 to 40 years with a body mass index (BMI) between 27 and 35 kg/m² participated in a single-center, randomized, four-group clinical trial conducted at Hospital Médica Campestre in León, Guanajuato, Mexico. Participants were assigned to lifestyle modification alone or lifestyle modification combined with phentermine at doses of 15 mg, 30 mg, or 37.5 mg daily. Phentermine was administered intermittently using a schedule of three months of treatment followed by one month without medication during a 14-month observation period. All participants received nutritional guidance and physical activity recommendations. Body composition was assessed using bioelectrical impedance analysis and three-dimensional body scanning. The primary outcome was the relative percentage reduction in total body fat from baseline to Month 14. Secondary outcomes included estimated visceral adiposity, waist circumference, lean body mass, body weight, BMI, medication adherence, resting heart rate, blood pressure, treatment-emergent adverse events, and treatment discontinuation. The study aimed to evaluate the dose-response effects of intermittent phentermine on body composition and the balance between efficacy and tolerability.

Conditions

  • Obesity & Overweight

Interventions

  • Phentermine 15 MGDrug

    Oral phentermine hydrochloride 15 mg administered once daily during active-treatment periods using a planned intermittent schedule of 3 months on treatment followed by 1 month off treatment, repeated over the 14-month observation period, in combination with structured lifestyle treatment.

  • Phentermine 30 mgDrug

    Oral phentermine hydrochloride 30 mg administered once daily during active-treatment periods using a planned intermittent schedule of 3 months on treatment followed by 1 month off treatment, repeated over the 14-month observation period, in combination with structured lifestyle treatment.

  • Phentermine 37.5 MgDrug

    Oral phentermine hydrochloride 37.5 mg administered once daily during active-treatment periods using a planned intermittent schedule of 3 months on treatment followed by 1 month off treatment, repeated over the 14-month observation period, in combination with structured lifestyle treatment.

  • Lifestyle ManagementBehavioral

    Structured lifestyle treatment targeting an energy deficit of approximately 500 kcal/day and approximately 150 minutes/week of aerobic physical activity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative Percentage Reduction in Total Body Fat from BaselineTime frame: Baseline through Month 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Medica Campestre

    León, Guanajuato, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.